All In Biotech

Drug Trial Radar · NCT04984837

Study of Lacutamab in Peripheral T-cell Lymphoma

A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Oct 5, 2021

Primary completion

Apr 30, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Innate Pharma
First posted
Aug 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label multicenter randomized non comparative phase II study to evaluate the safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL). The design is non comparative meaning that non comparison between arms will be performed as the control arm will ensure that the assumptions used for sample size calculation are verified. For that reason, randomization is unbalanced in favor of the experimental arm (2:1).

Conditions

  • Peripheral T Cell Lymphoma
  • Relapse/Recurrence

Interventions

  • LacutamabDrug

    750 mg/IV

  • GemcitabineDrug

    1000 mg/m²

  • OxaliplatineDrug

    100 mg/m²

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. median modified progression-free survival (mPFS) - CT-basedTime frame: 5,5 years.

Locations

64 sites in 4 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Anderlecht, Belgium

  • VZW ZAS

    Antwerp, Belgium

  • A. Z. Sint-Jan

    Bruges, Belgium

  • Cliniques Universitaires de Bruxelles - Hôpital Erasme

    Brussels, Belgium

  • Cliniques universitaires Saint-Luc - Université catholique de Louvain

    Brussels, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • HELORA - Hôpital de La LouvièreSite Jolimont

    Haine-Saint-Paul, Belgium

  • CHU de LIEGE - Domaine Sart Tilman

    Liège, Belgium

  • Clinique CHC MontLégia

    Liège, Belgium

  • CHR Verviers

    Verviers, Belgium

  • CHU Dinant Godinne - UCL Namur - YVOIR

    Yvoir, Belgium

  • CHU d'Amiens

    Amiens, France

  • CHU d'Angers

    Angers, France

  • CH d Avignon - Hopital Henri Duffaut

    Avignon, France

  • CH de la Côte Basque - Hôpital de Bayonne

    Bayonne, France

  • Institut Bergonié

    Bordeaux, France

  • CHU de Caen - Côte de Nacre - IHBN

    Caen, France

  • CH Métropole Savoie

    Chambéry, France

  • CHU de Clermont Ferrand - Estaing

    Clermont-Ferrand, France

  • APHP - Hôpital Henri Mondor

    Créteil, France

  • CHU de Dijon BOURGOGNE - Hôpital François Mitterand

    Dijon, France

  • CH de Dunkerque

    Dunkirk, France

  • CHD de Vendée

    La Roche-sur-Yon, France

  • CHU de Grenoble - Hôpital Albert Michallon

    La Tronche, France

  • Ch de Versailles - Hopital Andre Mignot

    Le Chesnay, France

  • CH du Mans

    Le Mans, France

  • CHRU de Lille - Hôpital Claude Hurriez

    Lille, France

  • Hôpital Saint Vincent-De-Paul

    Lille, France

  • Chu de Limoges - Hopital Dupuytren

    Limoges, France

  • Centre Leon Berard

    Lyon, France

  • Chu de Meaux

    Meaux, France

  • CHU de Montpellier

    Montpellier, France

  • CH de Mulhouse

    Mulhouse, France

  • CHU de Nancy - Brabois

    Nancy, France

  • CHU de Nantes - Hôtel Dieu

    Nantes, France

  • CHU de Nîmes

    Nîmes, France

  • CHR d'Orléans

    Orléans, France

  • APHP - Hopital Necker

    Paris, France

  • APHP - Hôpital de la Pitié Salpétrière

    Paris, France

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.